

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	1
METHODOLOGY .....	2
RELATED BCC STUDIES .....	2
ANALYST CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER .....	3
CHAPTER TWO: SUMMARY.....	4
THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY</i>	
<i>PRODUCT SEGMENT, THROUGH 2014 (\$ MILLIONS)</i> .....	5
<i>SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY</i>	
<i>PRODUCT SEGMENT, 2007-2014 (\$ MILLIONS)</i> .....	5
CHAPTER THREE: INDUSTRY OVERVIEW.....	6
OVERVIEW.....	6
HISTORY OF THE MARKET .....	6
EPIDEMICS/PANDEMICS .....	6
Spanish Influenza 1918–1919.....	6
Asian Influenza 1957.....	7
Hong Kong Influenza 1968.....	7
Swine Flu 1976 .....	7
Russian Influenza 1977.....	7
Avian Flu 1961, 1997, 2003–2009 (sporadic).....	8
Novel Influenza H1N1 2009.....	8
VIRUS MUTATIONS.....	9
TYPES OF INFLUENZA .....	9
Influenza Type A .....	10
Influenza A H5.....	10
Influenza A H7.....	10
Influenza A H9.....	10
Influenza A H1.....	10
Influenza Type B .....	11
Influenza Type C .....	11
WORLD ACTIVITY OF INFLUENZA VIRUSES.....	11
<i>TABLE 1 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES</i>	
<i>AFFECTED BY TYPE</i> .....	11
<i>TABLE 1 (CONTINUED)</i> .....	12
THE WORLD HEALTH ORGANIZATION (WHO) AND THE	
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC):	
INFLUENZA RESPONSE .....	13
WORLD HEALTH ORGANIZATION .....	13

CENTERS FOR DISEASE CONTROL AND PREVENTION .....	13
American Recovery and Reinvestment Act (ARRA) of 2009.....	14
U.S. VIRAL SURVEILLANCE.....	14
<i>TABLE 2 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS</i>	
<i>TYPE, 2005–2009 FLU SEASONS</i> .....	15
VACCINE RECOMMENDATIONS .....	15
<i>TABLE 3 THIMEROSAL CONTENT OF INFLUENZA VACCINES</i> .....	16
<i>TABLE 4 CDC INFLUENZA VACCINE RECOMMENDATIONS</i> .....	17
DEVELOPMENT OF FLU VACCINES.....	17
<i>TABLE 5 MIDAS RESEARCH TEAMS AND AREAS OF STUDY</i> .....	18
UNIVERSAL VACCINE .....	18
WORLD DEMOGRAPHICS AND INFLUENZA	
INCIDENCE/MORTALITY .....	18
<i>TABLE 6 ESTIMATED WORLD POPULATION AND ANNUAL</i>	
<i>GROWTH, BY SELECTED AGE GROUP AND SELECTED YEARS</i>	
<i>THROUGH 2030 (# MILLIONS)</i> .....	19
<i>FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE</i>	
<i>GROUP AND SELECTED YEARS 2000–2030 (# MILLIONS)</i> .....	19
<i>TABLE 7 POPULATION BY SELECTED COUNTRIES, THROUGH</i>	
<i>2014 (MILLIONS)</i> .....	20
<i>FIGURE 2 POPULATION BY SELECTED COUNTRIES, 2007–2014 (\$</i>	
<i>MILLIONS)</i> .....	21
<i>TABLE 8 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON</i>	
<i>2009 DATA AND POPULATION</i> .....	21
<i>TABLE 9 UNITED STATES VIRAL STATISTICS, ESTIMATED ON</i>	
<i>2009 DATA AND POPULATION</i> .....	22
CHAPTER FOUR: ISSUES AFFECTING THE MARKET .....	23
H1N1 OUTBREAK 2009 (SWINE FLU).....	23
DIAGNOSTICS .....	23
AVIAN FLU.....	24
U.S. GOVERNMENT INTERVENTION.....	24
<i>TABLE 10 COUNTRIES AFFECTED BY CURRENT CDC AND USDA</i>	
<i>BIRD IMPORT RESTRICTIONS</i> .....	25
AVIAN FLU SURVEILLANCE .....	26
<i>TABLE 11 WHO–REPORTED CASES OF AVIAN INFLUENZA</i>	
<i>A/(H5N1) IN HUMANS</i> .....	26
<i>FIGURE 3 WHO–REPORTED CASES OF AVIAN INFLUENZA A/</i>	
<i>(H5N1) IN HUMANS, 2003-2009</i> .....	27
THE WHO AND CONTAINMENT ISSUES FOR	
PANDEMIC INFLUENZA.....	27
<i>TABLE 12 APPROVED WHO INFLUENZA CENTERS BY REGION</i> .....	28
<i>TABLE 12 (CONTINUED)</i> .....	29
<i>TABLE 12 (CONTINUED)</i> .....	30
<i>TABLE 12 (CONTINUED)</i> .....	31

<i>TABLE 12 (CONTINUED)</i> .....	32
<i>TABLE 12 (CONTINUED)</i> .....	33
<i>TABLE 12 (CONTINUED)</i> .....	34
<i>TABLE 13 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003-MAY 2009 (SUBTYPE H5N1 IN POULTRY)</i> .....	35
<i>TABLE 13 (CONTINUED)</i> .....	36
<i>FIGURE 4 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE (%)</i> .....	36
<i>FIGURE 4 (CONTINUED)</i> .....	37
INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS.....	37
PRE-PANDEMIC VACCINATION.....	37
ANTIVIRAL RESISTANCE.....	38
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE'S (HHS) CONTRACTS FOR INFLUENZA PREPAREDNESS.....	38
<i>TABLE 14 ORDERS OF BULK SUPPLY NOVEL H1N1 VACCINE ANTIGEN AND ADJUVANT, 2009 (\$ MILLIONS)</i> .....	39
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA).....	39
HHS CONTRACTS FOR RELATED TECHNOLOGIES.....	39
PREVIOUS U.S. VACCINE CONTRACTS.....	40
RECREATED VIRUSES.....	40
IMMATERIALIZED MARKET RISK.....	41
MEDIA COVERAGE AND VACCINATIONS.....	42
EPIDEMIC/PANDEMIC THREAT.....	42
<i>TABLE 15 ESTIMATED INCIDENCE OF NOVEL H1N1 INFLUENZA FOR 2009 SECOND WAVE IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)</i> .....	43
<i>TABLE 15 (CONTINUED)</i> .....	44
WORLD INFLUENZA IMPACT.....	45
SEASONAL FLU ECONOMIC IMPACT IN THE U.S. ....	45
HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC.....	45
CHAPTER FIVE: PATENT ANALYSIS.....	46
OVERVIEW.....	46
INFLUENZA PATENTS BY PATENT NUMBER.....	46
<i>TABLE 16 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER</i> .....	47
<i>TABLE 16 (CONTINUED)</i> .....	48
<i>TABLE 16 (CONTINUED)</i> .....	49
<i>TABLE 17 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR</i> .....	50

**FIGURE 5 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET**

<b>COMPETITOR</b> .....	<b>51</b>
ABBOTT LABORATORIES .....	52
AMGEN .....	52
MEDIMMUNE/AVIRON .....	52
BAXTER HEALTHCARE .....	53
BIOTA SCIENTIFIC.....	53
CONNAUGHT LABORATORIES, INC. ....	53
CRUCCELL HOLLAND B.V.....	54
GLAXOSMITHKLINE .....	54
MERCCK & CO. INC.....	54
NOVARTIS VACCINES/CHIRON .....	55
PROTEIN SCIENCES CORP. ....	55
YEDA RESEARCH AND DEVELOPMENT .....	55
CHAPTER SIX: INFLUENZA THERAPIES/VACCINES .....	56
OVERVIEW.....	56
CURRENT VACCINES .....	56
CSL BIOTHERAPIES.....	56
GLAXOSMITHKLINE .....	57
MEDIMMUNE .....	57
NOVARTIS .....	57
SANOFI PASTEUR.....	58
SOLVAY PHARMACEUTICALS .....	58
TABLE 18 MARKETED VACCINE PRODUCTS, THROUGH 2009 .....	58
SEASONAL 2008/2009 VACCINE APPROVALS.....	59
TABLE 19 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2008–2009 INFLUENZA SEASON.....	59
CURRENT THERAPIES .....	59
TABLE 20 MARKETED THERAPIES, THROUGH 2009 .....	60
SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS.....	60
TABLE 21 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY AGE: UNITED STATES.....	60
TABLE 21 (CONTINUED).....	61
GENERIC AVAILABILITY .....	62
TABLE 22 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS .....	62
VACCINE AND BIOLOGICAL DEVELOPMENTS.....	62
ACAMBIS PLC .....	62
ALNYLAM PHARMACEUTICALS.....	63
ALPHAVAX .....	63
BIOCRYST PHARMACEUTICALS .....	63
BIONDVAX .....	63
BIOTA HOLDINGS AND SANKYO COMPANY, LTD.....	63

CRUCCELL.....	64
CURELAB .....	64
CYTOGENIX .....	64
DYNAVAX TECHNOLOGIES.....	64
GENEREX BIOTECHNOLOGY.....	65
GLAXOSMITHKLINE .....	65
HEMISPHERX BIOPHARMA.....	65
IMMUNEREGEN BIOSCIENCES, INC.....	66
INTERCELL.....	66
MEDIMMUNE .....	66
NANOVIRICIDES, INC.....	66
NEXBIO, INC.....	67
NOBILON.....	67
NOVARTIS VACCINES.....	67
NOVAVAX, INC. ....	67
PROTEIN SCIENCES CORPORATION.....	68
SANOFI PASTEUR.....	68
SOLVAY PHARMACEUTICALS .....	68
SINOVAC BIOTECH .....	69
TOYAMA CHEMICAL.....	69
VAXIN, INC.'S.....	69
VAXINNATE .....	69
VICAL, INC. ....	69
<i>TABLE 23 RESEARCH AND DEVELOPMENT EFFORTS BY</i>	
<i>PROGRESS.....</i>	<i>70</i>
<i>TABLE 23 (CONTINUED).....</i>	<i>71</i>
<i>TABLE 23 (CONTINUED).....</i>	<i>72</i>
<i>CLINICAL TRIALS.....</i>	<i>72</i>
<i>TABLE 24 CLINICAL TRIALS FOR INFLUENZA BY SELECTED</i>	
<i>COUNTRY AND TRIAL STATUS.....</i>	<i>73</i>
<i>FIGURE 6 CLINICAL TRIALS FOR INFLUENZA BY SELECTED</i>	
<i>COUNTRY AND TRIAL STATUS.....</i>	<i>73</i>
<i>RECENT INDUSTRY NEWS .....</i>	<i>74</i>
<i>MARKET ANALYSIS .....</i>	<i>74</i>
<i>TABLE 25 REVENUES FOR INFLUENZA THERAPEUTICS AND</i>	
<i>VACCINES BY MARKET, THROUGH 2014 (\$ MILLIONS).....</i>	<i>75</i>
<i>FIGURE 7 REVENUES FOR INFLUENZA THERAPEUTICS AND</i>	
<i>VACCINES BY MARKET, 2007-2014 (\$ MILLIONS).....</i>	<i>75</i>
<i>TABLE 26 REVENUES FOR INFLUENZA THERAPEUTICS AND</i>	
<i>VACCINES BY PRODUCT TYPE, THROUGH 2014 (\$ MILLIONS).....</i>	<i>76</i>
<i>FIGURE 8 REVENUES FOR INFLUENZA THERAPEUTICS AND</i>	
<i>VACCINES BY PRODUCT TYPE, 2007-2014 (\$ MILLIONS).....</i>	<i>76</i>
<i>THE GLOBAL INFLUENZA VACCINE MARKET .....</i>	<i>77</i>

<i>TABLE 27 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	77
<i>FIGURE 9 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	78
<i>TABLE 28 UNITS FOR INFLUENZA VACCINES BY PRODUCT AND MANUFACTURER, 2005–2008 (MILLIONS)</i> .....	79
<i>FIGURE 10 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2005–2006 SEASON (MILLIONS)</i> .....	79
<i>FIGURE 11 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2006–2007 SEASON (MILLIONS)</i> .....	80
<i>FIGURE 12 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2008 SEASON (MILLIONS)</i> .....	80
The U.S. Influenza Vaccine Market.....	81
<i>TABLE 29 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	82
<i>FIGURE 13 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	82
<i>TABLE 30 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005–2009</i> .....	83
<i>FIGURE 14 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005–2009</i> .....	83
<i>TABLE 31 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008–2009 (UNITS PER MILLION)</i> .....	84
<i>FIGURE 15 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008–2009 SEASON (%)</i> .....	84
The European Influenza Vaccine Market.....	84
<i>TABLE 32 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	85
<i>FIGURE 16 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	85
THE GLOBAL INFLUENZA THERAPEUTICS MARKET.....	86
<i>TABLE 33 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	86
<i>FIGURE 17 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	87
Influenza Therapeutics Market in the United States.....	87
<i>TABLE 34 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	87
<i>FIGURE 18 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	88
Influenza Therapeutics Market in Europe.....	88

<i>TABLE 35 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	88
<i>FIGURE 19 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007–2009 (\$ MILLIONS)</i> .....	89
COMPETITOR ANALYSIS .....	89
COMPETITOR ANALYSIS (CONTINUED).....	90
<i>TABLE 36 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007–2009 (%)</i> .....	91
<i>FIGURE 20 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007 (%)</i> .....	91
<i>FIGURE 21 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2008 (%)</i> .....	92
<i>FIGURE 22 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2009 (%)</i> .....	92
CHAPTER SEVEN: INFLUENZA DIAGNOSTICS.....	93
OVERVIEW.....	93
<i>TABLE 37 INFLUENZA DIAGNOSTIC TABLE</i> .....	93
<i>TABLE 37 (CONTINUED)</i> .....	94
PRODUCT DESCRIPTION .....	94
Conventional Laboratory Tests.....	94
Applied Biosystems.....	94
Qiagen, Inc. ....	95
<i>TABLE 38 EXAMPLES OF CONVENTIONAL LABORATORY TESTS FOR INFLUENZA</i> .....	95
Rapid Testing.....	96
3M and Response Biomedical.....	96
Becton Dickinson .....	96
Diagnostic Hybrids .....	97
Genzyme Diagnostics.....	97
Inverness Laboratories .....	97
Luminex .....	97
Prodesse, Inc. ....	98
Quidel .....	98
Remel, Inc.....	98
SA Scientific, Ltd. ....	98
<i>TABLE 39 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH JUNE 2009</i> .....	99
<i>TABLE 40 RAPID INFLUENZA TESTS AVERAGE PRICE (\$)</i> .....	100
LABORATORY SERVICES .....	100

Associated Regional University Pathologists (ARUP)	
Laboratories.....	100
Bio–Reference Laboratories, Inc.....	100
Laboratory Corporation of America .....	101
Pathology Associates Medical Laboratories .....	101
Quest Diagnostics.....	101
Specialty Laboratories.....	102
ViroMed Laboratories, Inc. ....	102
<i>TABLE 41 PROVIDERS OF TEST SERVICES.....</i>	<i>102</i>
INDUSTRY DEVELOPMENTS .....	102
MARKET ANALYSIS .....	103
<i>TABLE 42 REVENUES FOR INFLUENZA DIAGNOSTICS BY</i>	
<i>MARKET, THROUGH 2014 (\$ MILLIONS).....</i>	<i>104</i>
<i>FIGURE 23 REVENUES FOR INFLUENZA DIAGNOSTICS BY</i>	
<i>MARKET, 2007-2014 (\$ MILLIONS).....</i>	<i>104</i>
<i>TABLE 43 REVENUES FOR INFLUENZA DIAGNOSTICS BY</i>	
<i>PRODUCT TYPE, THROUGH 2014 (\$ MILLIONS).....</i>	<i>105</i>
<i>FIGURE 24 REVENUES FOR INFLUENZA DIAGNOSTICS BY</i>	
<i>PRODUCT TYPE, 2007-2014 (\$ MILLIONS).....</i>	<i>106</i>
MANUFACTURER REVENUES .....	106
<i>TABLE 44 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS</i>	
<i>BY MANUFACTURER, 2007–2009 (\$ MILLIONS).....</i>	<i>107</i>
<i>FIGURE 25 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS</i>	
<i>BY MANUFACTURER, 2007–2009 (\$ MILLIONS).....</i>	<i>107</i>
CHAPTER EIGHT: MARKET SUMMARY .....	108
TOTAL MARKET ANALYSIS.....	108
<i>TABLE 45 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE</i>	
<i>SEGMENT, THROUGH 2014 (\$ MILLIONS).....</i>	<i>109</i>
<i>FIGURE 26 GLOBAL INFLUENZA MARKET ANALYSIS, BY</i>	
<i>REVENUE SEGMENT, 2007-2014 (\$ MILLIONS).....</i>	<i>109</i>
INDUSTRY PARTICIPANTS.....	109
<i>TABLE 46 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT</i>	
<i>SEGMENT, INDUSTRY PARTICIPANTS BY TYPE .....</i>	<i>110</i>
CHAPTER NINE: COMPANY PROFILES .....	111
ASTRAZENECA/MEDIMMUNE .....	111
<i>TABLE 47 ASTRAZENECA’S COMPANY REVENUES, 2006–2009 (\$</i>	
<i>MILLIONS).....</i>	<i>112</i>
<i>FIGURE 27 ASTRAZENECA’S COMPANY REVENUES 2006–2009 (\$</i>	
<i>MILLIONS).....</i>	<i>112</i>
BECTON DICKINSON.....	113
<i>TABLE 48 BECTON DICKINSON’S COMPANY REVENUES, 2006–2009</i>	
<i>(\$ MILLIONS).....</i>	<i>113</i>

<i>FIGURE 28 BECTON DICKINSON'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	114
CSL BIOTHERAPIES.....	114
<i>TABLE 49 CSL LIMITED'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	115
<i>FIGURE 29 CSL LIMITED'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	115
GLAXOSMITHKLINE.....	116
<i>TABLE 50 GLAXOSMITHKLINE'S COMPANY REVENUES 2006–2009 (\$ MILLIONS)</i> .....	117
<i>FIGURE 30 GLAXOSMITHKLINE'S COMPANY REVENUES 2006–2009 (\$ MILLIONS)</i> .....	117
INVERNESS MEDICAL.....	117
<i>TABLE 51 INVERNESS MEDICAL'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	118
<i>FIGURE 31 INVERNESS MEDICAL'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	118
NOVARTIS VACCINES AND DIAGNOSTICS.....	119
<i>TABLE 52 NOVARTIS' COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	120
<i>FIGURE 32 NOVARTIS' COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	120
QUIDEL.....	121
<i>TABLE 53 QUIDEL'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	121
<i>FIGURE 33 QUIDEL'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	122
ROCHE.....	122
<i>TABLE 54 ROCHE GROUP'S REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	123
<i>FIGURE 34 ROCHE GROUP'S REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	124
SANOFI–AVENTIS/SANOFI PASTEUR.....	124
SANOFI–AVENTIS/SANOFI PASTEUR (CONTINUED).....	125
<i>TABLE 55 SANOFI–AVENTIS' COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	126
<i>FIGURE 35 SANOFI–AVENTIS' COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	126
SOLVAY.....	126
<i>TABLE 56 SOLVAY'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	127
<i>FIGURE 36 SOLVAY'S COMPANY REVENUES, 2006–2009 (\$ MILLIONS)</i> .....	127
APPENDIX.....	128
MANUFACTURERS AND DEVELOPERS.....	128
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	129

MANUFACTURERS AND DEVELOPERS (CONTINUED).....	130
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	131
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	132
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	133
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	134
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	135
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	136
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	137
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	138
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	139
MANUFACTURERS AND DEVELOPERS (CONTINUED).....	140
MENTIONED UNIVERSITIES .....	141
RELEVANT ASSOCIATIONS AND ORGANIZATIONS.....	142
RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED).....	143
RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED).....	144